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Abstract
One of the key questions about genomic alterations in cancer is whether they are functional in the sense of contributing to
the selective advantage of tumor cells. The frequency with which an alteration occurs might reflect its ability to increase
cancer cell growth, or alternatively, enhanced instability of a locus may increase the frequency with which it is found to be
aberrant in tumors, regardless of oncogenic impact. Here we’ve addressed this on a genome-wide scale for cancerassociated focal deletions, which are known to pinpoint both tumor suppressor genes (tumor suppressors) and unstable
loci. Based on DNA copy number analysis of over one-thousand human cancers representing ten different tumor types, we
observed five loci with focal deletion frequencies above 5%, including the A2BP1 gene at 16p13.3 and the MACROD2 gene at
20p12.1. However, neither RNA expression nor functional studies support a tumor suppressor role for either gene. Further
analyses suggest instead that these are sites of increased genomic instability and that they resemble common fragile sites
(CFS). Genome-wide analysis revealed properties of CFS-like recurrent deletions that distinguish them from deletions
affecting tumor suppressor genes, including their isolation at specific loci away from other genomic deletion sites, a
considerably smaller deletion size, and dispersal throughout the affected locus rather than assembly at a common site of
overlap. Additionally, CFS-like deletions have less impact on gene expression and are enriched in cell lines compared to
primary tumors. We show that loci affected by CFS-like deletions are often distinct from known common fragile sites.
Indeed, we find that each tumor tissue type has its own spectrum of CFS-like deletions, and that colon cancers have many
more CFS-like deletions than other tumor types. We present simple rules that can pinpoint focal deletions that are not CFSlike and more likely to affect functional tumor suppressors.
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breaks when the cell is exposed to partial replication stress [1,2].
Cancer cells frequently show hemizygous or homozygous deletions
at these loci and in addition there are often expression alterations
of the underlying gene [3]. Tumor suppressor functions have been
found for some of these genes, including WWOX, FHIT, and
PARK2, and these functions include growth suppressive effects of
restoring expression in deficient cell lines and loss-of-function
mutations leading to enhancement of carcinogen-induced or
genetically-engineered cancer in mice [3,4,5]. Other studies have
made observations that do not support a tumor suppressor role for
these genes, including the inability to detect inactivating point
mutations [6,7] and the frequent failure of deletions to affect
underlying RNA or protein expression [7,8], both of which are
common features of other tumor suppressor genes.

Introduction
In human cancer it is generally the case that highly recurrent
point mutations, such as those occurring in KRAS or TP53,
contribute to the selective advantage of tumor cells. However the
case is less clear with DNA copy number alterations, where some
frequent alterations such as amplification of the ERBB2/HER2
locus clearly provide a selective advantage, whereas others like the
frequent deletions of DNA at the telomeric ends of chromosomes
likely do not. This means that alteration frequency alone is not
sufficient to determine whether or not a given DNA copy number
alteration directly impacts oncogenicity. Nowhere has this been
more difficult to tease out than for candidate tumor suppressor
genes located within common fragile sites. Common fragile sites
are found throughout the human genome and are prone to DNA
PLOS ONE | www.plosone.org
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encodes an alternative splicing factor, is restricted to the heart,
muscle, and brain [19]. Although we cannot rule out very lowlevel but physiologically relevant expression of A2BP1 in colon
samples, we did not observe any growth suppressive or tumor
suppressive effects of expressing A2BP1 in colon cancer cell lines
harboring deletions (Figure 2B). Additionally, although MACROD2
is expressed in colon cancer cells, deletions had no effect on
expression as measured by quantitative RT-PCR using four
different probes including three within coding sequences and one
in the 39 untranslated region. Nor did deletions have any
appreciable effect on expression of MacroD2 protein (Figure 2C).
Although seemingly paradoxical, these deletions all occurred
within introns of MACROD2 and therefore would not necessarily
be expected to affect expression.

Previously we discovered and validated 26 oncogenes by
functionally screening sets of genes that are focally amplified in
human cancer and similarly have validated 10 tumor suppressor
genes that were found in focal deletions affecting liver cancer
[9,10,11,12,13,14,15]. We began this study with the goal of
validating two tumor suppressor gene candidates that were focally
deleted at high frequency particularly in colorectal cancer, A2BP1
and MACROD2. In contrast to the results obtained by screening
focal deletions in liver cancer, we did not find that these genes
were tumor suppressors, which prompted us to take a genomewide look at the properties of focally deleted genes in a large
dataset of DNA copy number alterations affecting over 1000
cancer samples. This led to the discovery of two classes of focal
deletions in human cancer, one that resembles deletions affecting
common fragile sites and the other that resembles deletions
affecting CDKN2A/B. Since then, a genome-wide examination of
small homozygous deletions in 270 human cancer cell lines has
been reported that also finds two classes of focal deletions [16],
and while our conclusions are largely similar to theirs, there are
some important distinctions and nuances about the two classes and
additional findings which are described below.

Patterns of Deletions Affecting A2BP1, MACROD2,
CDKN2A/B, and PTEN
We noted several differences in the types and patterns of
deletions affecting A2BP1 and MACROD2 loci when compared to
focal deletions affecting CDKN2A/B and PTEN loci (Figure 3). By
examining all focal deletions (,10 Mb) that spanned a four Mb
locus centered on the target gene, we found that deletions affecting
the A2BP1 and MACROD2 loci were on average smaller (0.6 Mb
vs. 1.6 Mb, p = 1.5e-04). Additionally, the deletions affecting the
A2BP1 and MACROD2 loci were more separated and the majority
did not converge upon a single common site of overlap, in contrast
to CDKN2A/B and PTEN loci (Figure 3). We measured the degree
to which each deletion was separate (non-overlapping) from other
deletions (‘‘Deletion Separation’’, see Materials and Methods) and
found that there was a significant difference between the A2BP1
and MACROD2 loci and the CDKN2A/B and PTEN loci (0.4 vs.
0.16, p = 0.03).
We then wanted to determine if these two distinctions between
deletions affecting A2BP1 and MACROD2 loci on the one hand
and CDKN2A/B and PTEN loci on the other hand held true when
comparing deletions affecting known common fragile sites and
recessive tumor suppressor genes from the Cancer Gene Census
[20,21]. In our dataset, there were 11 common fragile sites and 24
recessive tumor suppressor genes that contained a sufficient sample
size of deletions (.14) for this statistical analysis (Table S4).
Similar to what we observed above, in this larger set of loci the
average deletion size affecting common fragile sites was significantly smaller than those affecting recessive tumor suppressors
(0.6 Mb vs. 3.3 Mb, p = 9e-06, Figure 4A). Likewise, the ‘‘Deletion
Separation’’ metric was significantly greater in common fragile
sites than it was in recessive tumor suppressor genes (Figure 4B).
This latter result suggests that deletions affecting these two groups
arise by different mechanisms. Deletions in common fragile site
genes can be induced by replicative stress and subsequent DNA
damage and repair [22], deletions affecting CDKN2A/B have been
suggested to arise from aberrant recombination or DNA repair by
nonhomologous end-joining [23]. In support of the idea that these
two types of deletions arise by separate mechanisms, we found that
the frequency of co-occurrence of deletions in different common
fragile site genes and co-occurrence of deletions in different tumor
suppressor genes was greater than that of co-deletion of CFS and
tumor suppressor genes (Figure 4C).

Results
Common Sites of Focal Deletions in Human Cancer
Our dataset was generated by array CGH analysis of 850
primary tumors and 304 cancer cell lines or xenografts of diverse
tissue types including brain, breast, colon, liver, lung, ovarian,
pancreatic, prostate, and skin (melanoma) (Table S1). Following
data normalization and segmentation we detected a total of 10,835
focal deletions (,10 Mb) in these 1,154 samples (Table S2). The
average size of deletions, both focal and large, is the shortest at
telomeres as expected (Figure 1A, Figure S1 in File S1) and
therefore a substantial percentage (13%) of focal deletions involved
telomeric ends, particularly both ends of the X chromosome and
the p arm of chromosome 4 (Table S3). Figure 1 shows the
distribution of the other 87% of focal deletions across the genome,
binned into 2-Mb intervals. There were five loci that showed focal
deletion frequencies greater than 5% and they corresponded to the
CDKN2A/B, FHIT and WWOX loci, known or suspected tumor
suppressor genes, and the MACROD2 and A2BP1 loci (Figure 1B).
Deletions affecting A2BP1 (also known as RBFOX1) were very
frequent in colorectal cancer (21%) but considerably less frequent
or absent in other tumor types (1–4% in ovarian, liver and lung
cancers and absent in breast, melanoma, prostate, and pancreatic
cancers). Similarly, deletions affecting MACROD2 were most
frequent in colorectal cancer (17%) but considerably less frequent
or absent in other tumor types (0.5–3% in breast, liver and lung
cancers and absent in ovarian, melanoma, prostate, and pancreatic cancers). Frequent deletions affecting A2BP1 and MACROD2
in colon cancer have been observed by others [17,18].

Examination of A2BP1 and MACROD2 as Potential Tumor
Suppressor Genes
We examined the effects of A2BP1 and MACROD2 deletions on
underlying gene expression in colon cancers and normal colon
tissues. RNA expression of A2BP1 could not be detected by realtime RT-PCR in any of the normal colon tissues, tumors, or
cancer cell lines that we examined (Figure 2A). To help confirm
this negative result, we designed three additional probes for realtime RT-PCR and standard RT-PCR, but in each case failed to
detect A2BP1 in colon samples, despite being able to readily detect
its expression in the brain (Figure 2A). These results are consistent
with a prior report that expression of A2BP1/RBFOX1, which
PLOS ONE | www.plosone.org

Additional Properties that Distinguish Deletions Affecting
Common Fragile Sites
We next wanted to determine whether the inability of deletions
to affect expression of MACROD2 was a more generalizable
observation that could be used to distinguish common fragile site2
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Figure 1. Sites in the genome of frequent cancer focal deletions. (A) Average DNA segment size as a function of position on chromosome 1 is
displayed. (B) the 9,401 focal deletions that were not telomeric were binned into 2 Mb intervals and used to generate a frequency distribution across
the genome. The most frequently affected genomic interval corresponded to the CDKN2A/B locus and the next six most frequently affected genomic
intervals are indicated with red arrows and the relevant gene.
doi:10.1371/journal.pone.0066264.g001

like genes from tumor suppressor genes. We determined the
correlation of RNA expression and DNA copy number for 115
cancer samples where we had both gene expression profiling and
ROMA aCGH data. Compared to the correlations of the tumor
suppressor group, there was very little effect of DNA copy number
on gene expression in the common fragile site group (p = .003,

PLOS ONE | www.plosone.org

Figure 5A), indicating that this feature could be useful in
predicting whether or not a given site of deletions was CFS-like.
We then examined whether the average DNA copy number value
was significantly different, which reflects the degree to which
deletions were homozygous versus heterozygous. Even though
there wasn’t a statistically significant difference between the
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Figure 2. Expression and tumor suppressive properties of A2BP1 and MACROD2. (A) Threshold PCR cycles for RT-PCR detection of ACTB
(control) and A2BP1 in two different samples of normal brain tissue, four different samples of normal colon tissue, and 19 colon cancer cell lines.
Values below 40 indicate no signal detection. (B) The effect of forced ectopic expression of A2BP1 on tumor formation of colon cancer cell line HCT15, which harbors a 250-kb deletion within A2BP1. Detection of expression by immunoblotting using a polyclonal antibody that recognizes the A2BP1
protein [38] is shown in the insert. Lack of tumor suppressive effects were also observed for the colon cancer cell lines HCT-116 and SW480, both
harboring deletions in A2BP1. (C) The expression of MACROD2 in colon cancer cell lines as determined by TaqMan RT-PCR using four different probes
(three to coding sequences and one to a 39 UTR, all unaffected by deletions), comparing cell lines that harbor deletions within the MACROD2 gene to
ones that do not. Relative expression was calculated by the DCT method using GADPH expression levels as the reference. (D) The expression of
MACROD2 in colon cancer cell lines as determined by immunoblotting using an antibody to MacroD2.
doi:10.1371/journal.pone.0066264.g002

By looking at genome coordinate plots of focal deletion
frequencies, we noted that the frequent deletions affecting
MACROD2 were relatively isolated along the genome and that
the frequency count fell precipitously to the genes immediately left
and right of MACROD2 (Figure 5D). This was very distinct from
the genome neighborhood of focal deletions affecting the tumor
suppressor genes TP53 and MAP2K4, which both formed peaks of
deletion counts but less dramatically in the context of genomic
regions with a higher overall rate of deletions (Figure 5E). We
wanted to determine whether this distinction was a generalizable
feature that distinguished common fragile site genes from tumor
suppressor genes, and developed a metric ‘‘Deletion Isolation’’
that measured how much the deletion frequency of a given gene
was greater than neighboring genes. This metric was considerably
higher in common site fragile genes than tumor suppressor genes
(.40-fold, p = 0.00001) (Figure 5F).

average DNA copy number values (p = .09), there did appear to be
greater range of lower values for the tumor suppressor group,
indicating that some of these genes have more homozygous
deletions than do common fragile site genes (Figure 5B).
We also found that deletions affecting common fragile sites were
more common in cancer cell lines than in primary tumors when
compared to deletions affecting tumor suppressors (p = 7e-05,
Figure 5C). This is particularly evident in breast cancer, where
MACROD2 and FHIT are deleted in 28% and 15% of breast
cancer cell lines, respectively, but either not at all (FHIT) or in only
one out of 255 primary tumors (MACROD2) (Table S5). FHIT was
co-deleted with MACROD2 in 75% of the cell lines with FHIT
deletion, indicating that for certain breast cancer cell lines,
replicative stress followed by DNA breakage and repair might
occur during adaptation to cell culture and affect multiple
common fragile site genes.

PLOS ONE | www.plosone.org
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Figure 3. The boundaries of focal deletions that affect the A2BP1, MACROD2, CDKN2A/B, and PTEN genes. Each of the four panels shows
(top) an ideogram of the chromosome on which the featured gene is located and (below) an expanded view of a 4-Mb region centered on the
featured gene, showing other genes in the area (location based on the UCSC Genome Browser). If the gene is large enough, the exon-intron structure
and/or transcriptional direction of the gene are indicated. For most genes, particularly in panels C and D, the genes are shown as rectangles due to
their smaller size. Shown below each expanded region are horizontal bars indicating the extent and boundaries of individual deletions in colon
tumors (Panels A and B; A2BP1 and MACROD2, respectively), lung tumors (Panel C; CDKN2A/B), or multiple tumor types (Panel D; PTEN). The featured
genes in Panels C and D are highlighted in green.
doi:10.1371/journal.pone.0066264.g003

showed that the majority of genes were most similar to recessive
tumor suppressor genes (Figure 6A). With one exception, common
fragile site genes were well separated from the main group and
were similar to only a small number of additional genes
(Figure 6A). This result indicated that most genes that are targeted
by focal deletions are similar to tumor suppressor genes, whereas
considerably fewer genes are similar to common fragile site genes.
To test this idea independently, we used supervised learning
methods (support vector machine and random forest [RF]) to
classify the 4,823 genes into CFS-like or tumor suppressor
categories. The results of these two methods were significantly
correlated (r = 0.72) and both classified most genes as tumor
suppressor like, in agreement with the unsupervised analysis
(Figure 5B). The three variables that were most important in the

Computational Analysis and Classification of Focal
Deletions
We wanted to use these six properties to analyze deletions on a
genome-wide scale. We restricted our attention to genes with
sufficient deletions in order to obtain statistically meaningful
results (.14 deletions; 4,823 genes). We first explored whether any
of the six properties were redundant by determining if they were
highly correlated with any of the other five. Although deletion size
was moderately correlated with deletion separation (r = 0.39), all of
the other pairwise correlations were negligible (ranging from
20.13 to 0.18), and we proceeded to include all six properties for
unsupervised analysis. We then transformed the six properties
using principal component analysis and plotted the 4,823 genes
using the first three principal components. The resultant graph
PLOS ONE | www.plosone.org
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MACROD2, 9% for FHIT and 9% for PARK2 (Figure 8A). None
of the other nine tumor types were as frequently affected. Lung
cancer was the next most affected, but curiously had a different
spectrum of frequencies, with LRP1B being the most frequently
deleted CFS-like gene at 4% (Figure 8A). Several cancers did not
appear to be affected at all, including glioblastomas, CLL, and
prostate cancers, and many had very low frequency of deletions of
CFS-like genes, including breast cancer, which showed PARK2 as
its most frequently deleted CFS-like gene at just above 2%
(Figure 8A).
The frequency and spectrum of deletions in CFS-like genes was
different for all tumor types when comparing cell lines to primary
tumors (Figure 8B). In colon cancer cell lines, deletions affected
FHIT in over 60% of the cell lines compared to 9% of primary
tumors. In breast cancer cell lines, FHIT was deleted in 10% of the
samples but not at all in primary tumors (Figure 8B). It seems
possible that this may reflect the plasticity of the genome at FRA3B
(the FHIT fragile site) under culture conditions, and the same may
hold true for the increased incidence of deletions in other CFS-like
genes when comparing cell lines to primary tumors.

The Most Frequently Deleted Fragile Site-like Genes and
Tumor Suppressor-like Genes

Figure 4. Deletion size and deletion separation can distinguish
common fragile sites from tumor suppressor genes. (A) Box and
whisker plots for ‘‘Deletion Size,’’ which measures the median size of
deletions within a 2-Mb window centered on the gene, common fragile
site genes (orange) and tumor suppressor genes (blue) (B) Box and
whisker plots for ‘‘Deletion Separation,’’ which measures the separation
(non-overlapping) of deletions within a 2-Mb window centered on the
gene, (C) The co-deletion tendency of common fragile site genes
(orange) and tumor suppressor genes (blue) relative to the co-deletion
of genes of different classes (gray).
doi:10.1371/journal.pone.0066264.g004

The ability to predict new tumor suppressors is more pertinent
to cancer biology than the ability to predict new fragile site genes.
We reasoned that those tumor suppressor-like genes most
frequently affected by focal deletions would be amongst the
strongest candidates (Table 1). Interestingly, focal deletions in only
two of the top ten genes have been previously described
(CDKN2A/B and MAP2K4 [25]). Of the other eight genes, one is
a tumor suppressor that is known to be inactivated by other
genetic mechanisms [26] (MEN1), and four are candidate tumor
suppressors based on either mutational analysis (CSMD1 [27]),
functional analysis (CDKN2AIP/CARF [28], MAD1L1 [29]), or
cancer-specific promoter hypermethylation (RRAD [30]). On the
other hand, two genes recently proposed to be tumor suppressors
based on their focal deletion in cancer, PDE4D [31] and LRP1B
[32], are amongst the top ten most frequently affected CFS-like
genes and accordingly may not be functional tumor suppressors
(Table 1).

RF classification were deletion size, deletion separation, and
deletion isolation (Table S6). Using just these three variables, we
generated a new RF classifier that yielded results that were 99%
identical with the original classifier, establishing these three
properties as the most critical determinants as to whether a given
pattern of focal deletions is CFS-like or tumor suppressor-like.

Validation of MACROD2 as a Common Fragile Site Gene
To test whether our classification could successfully predict new
common fragile site gene genes, we examined whether induction
of replicative stress in a colon cancer cell line can generate
deletions in MACROD2 or A2BP1, which, together with the known
common fragile site gene gene FHIT, are the three genes most
frequently affected by focal deletions in colon cancer. We designed
a custom tiling array for these three genes and then performed
aCGH, comparing the original cell line DNA to DNA from eight
different clones isolated after brief induction of replicative stress.
Four out of eight clones showed deletions within MACROD2, and
two out of eight clones showed deletions within FHIT (Figure 7).
This establishes that MACROD2, which was not previously shown
to be a common fragile site gene in lymphocytes, is indeed a
common fragile site gene when assayed in a colon cancer cell line.
The fact that MACROD2 was readily detected as a common fragile
site gene in colon cancer cells but not in lymphocytes is consistent
with prior evidence that different cell types show different profiles
of common fragile sites [24].

Discussion
We initiated this study to reconcile two disparate findings: the
absence of tumor suppressor candidates from two loci frequently
affected by focal deletions, and the ability of focal deletions to
enrich for tumor suppressors in a functional screen. Through
computational and statistical analysis of focal deletions present in
more than 1000 cancer samples, we defined two distinct classes of
deletions in cancer that resolve this incongruity: a class that
represents genes similar to common fragile site genes, and another
that is tumor suppressor-like. These two types of deletions are
likely to arise from different mechanisms, based on their different
deletion sizes and their tendency to co-occur. The one class of
deletions, when highly recurrent, overlap a common site and
significantly affect the expression of the underlying genes,
indicating that recurrence is driven by selective advantage to the
evolving tumor cells. In contrast, deletions in common fragile sitelike genes do not overlap a common site nor do they have
significant effects on underlying gene expression, all of which is
consistent with their recurrence being driven by the inherent
instability of the genomic locus rather than by selective advantage.
Our findings establish that most focal deletions belong to the
class that represents tumor suppressor-like genes and not common

Different Tumor Types have Different Frequencies and
Spectrums of Deletions within CFS-like Genes
Interestingly, we found that colon tumors were by far the most
frequently affected by focal deletions in CFS-like genes, with
deletion frequencies as high as 21% for A2BP1, 17% for
PLOS ONE | www.plosone.org
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Figure 5. Deletion properties that distinguish common fragile site genes from tumor suppressor genes. Scatter dot plots of values for
statistics that distinguish focal deletions affecting common fragile site (CFS) genes (orange) from tumor suppressor genes (blue). (A) ‘‘RNA/DNA
Correlation,’’ which corresponds to the Pearson’s correlation coefficient of log2-transformed DNA copy number values and relative RNA expression
values for the 115 tumor samples with both array CGH and RNA expression profiling data, (B) DNA Copy Number is the median value of segmented
DNA copy number values. (C) Cell Line Proportion’’ which provides a relative measure of how frequently deletions for a given gene are found in cell
lines rather than primary tumors. Panels (D) and (E) show the number of deletions found in each gene within a 10 Mb region centered on the
MACROD2 locus (D) and TP53 and MAP2K4 loci (E). (F) Box and whisker plots of ‘‘Deletion Isolation,’’ which measures how frequently neighboring
genes are deleted relative to the featured gene.
doi:10.1371/journal.pone.0066264.g005

fragile site genes. This is the only disagreement we have with a
recent study which suggests that most focal deletions in cancer are
fragile-like based in part on in part on their propensity to be
heterozygous rather than homozygous [16]. However, we believe

PLOS ONE | www.plosone.org

that this property is not useful as a classifier because several tumor
suppressors, including TP53 and CDH1, are affected by focal
heterozygous deletions. It may be many haploinsufficient tumor
suppressors, such as p27KIP1 [33], remain to be discovered, and
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Figure 6. Genome-wide analysis and classification of focal deletions in cancer. Genes that had 15 or more focal deletions (4,823) were
analyzed by the unsupervised learning method of Principal Component Analysis (PCA) and classified by two supervised learning methods, Support
Vector Machine (SVM) and Random Forest (RF). (A) Graph of the 4,826 genes based on their values for the first three principal components derived
from the seven deletion properties that distinguish common fragile site genes from tumor suppressor genes. Known common fragile site genes are
shown in blue, known tumor suppressors are shown in red, and all others are shown in green. Most known tumor suppressors are buried within the
major group of genes, whereas the known common fragile site genes, with one exception (LARGE), are clearly separated from the major group of
genes by their first and second principal component values. There are only a handful of other genes that are located near the known common fragile
site genes. (B) Graphical representation of the classification of the 4,826 genes based on their probability of being common fragile site genes by
Random Forest (y-axis) or Support Vector Machine (x-axis) classifiers. Both classifiers were trained on the 35 known CFS genes or tumor suppressors
(Table S4). The probability of being a tumor suppressor is one minus the CFS probability. Most genes are clustered together in the lower left
quadrant; therefore, both classifiers predict with high probability that most of these genes are tumor suppressors.
doi:10.1371/journal.pone.0066264.g006

From the six deletion properties that could be used to
distinguish CFS-like genes, machine learning analysis with the
random forests classifier determined that only three deletion
properties are necessary to classify genes as being CFS-like or not:
deletion size, deletion separation, and deletion isolation. These
properties should be useful for investigators interested in
determining if their particular deleted candidate tumor suppressor
gene is CFS-like or not.

computational tools that discount these would be misguided. In
some cases, homozygous deletion of a tumor suppressor might be
lethal, which could be the case for the spindle assembly checkpoint
gene MAD1L1 which we found here to be very frequently affected
by heterozygous focal deletions. Although MAD1L1 is not yet in
the COSMIC database of tumor suppressors, heterozygous
deletion of MAD1L1 has been shown to increase the incidence
of tumors caused by partial loss of TP53 in mice [29].
One of the most interesting findings of our study was the tumortype specific pattern of deletions in CFS-like genes. There appears
to be a clear distinction in many cases from known common fragile
site genes, which have been determined almost exclusively from
analysis of DNA breaks in lymphocytes [1]. Indeed, many of the
most commonly deleted CFS-like genes in cancer, including
A2BP1, MACROD2, and PDE4D, are not known common fragile
sites even in the most recent analyses [2]. Although we initially
hypothesized that significantly different chromatin structure within
different tissue types could underlie at least part of tumor-type
specific patterns of deletions in CFS and CFS-like genes, we
observed no correlation with chromatin structure as indicated by
DNAase I hypersensitivity data from ENCODE (Table S9). We
think a more likely explanation for the tissue-type diversity comes
from the findings that both replication origin setting and
replication timing are tissue specific in mammalian cells and that
this explains the diversity of common site breakage at the FRA3B
locus [34].

PLOS ONE | www.plosone.org

Methods
Online Access to Microarray Data
We have deposited the aCGH microarray data with the Gene
Expression Omnibus (GEO) repository, accessions GSE31586 and
GSE22916.

Tumor Samples, Xenografts, and Cell Lines
We analyzed 850 tumor samples for this study (Table S1). Many
of them have been previously described, including the 255 breast
cancer samples from the Cancer Center of the Karolinska
Institute, Sweden, and the Oslo University Hospital, Norway
[35]; the 161 lung cancer samples from the Cooperative Human
Tissue Network (CHTN) [9]; the 88 liver cancer samples from
CHTN and medical centers in Germany and Hong Kong [15];
and the 27 pancreatic cancer samples and 40 pancreatic cancer
xenografts from Johns Hopkins University and the Arizona
Cancer Center [36]. New to this study are samples that were
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Figure 7. Validation of MACROD2 as a common fragile site gene. (A) A schematic of the experiment, which used a custom tiling array to
determine if aphidicolin induction of replicative stress could generate focal deletions at three loci (A2BP1, MACROD2, and FHIT) in colon epithelial
cancer cells. No deletions affecting A2BP1 were observed in the 8 examined clones; 4 out of 8 clones had deletions affecting MACROD2; and 2 clones
had deletions affecting FHIT. (B) An example of an induced focal deletion affecting the MACROD2 locus. The x-axis represents an approximately 1-Mb
region spanning MACROD2. The blue lines represent the normalized DNA copy number values, and the orange lines represent the segmented DNA
copy number values. (C) An example of an induced focal deletion affecting FHIT. (D) An example of an unaffected locus (the HLA locus on
chromosome 6p).
doi:10.1371/journal.pone.0066264.g007

obtained after approval from their respective institutional review
boards as indicated below. All patients provided written informed
consent and samples were procured under the respective
Institutional Review Board approvals. These include 135 colon
cancer samples which were obtained from Case Western Reserve
University collected under an Institutional Review Board (IRB)
approved protocol at the Case Medical Center; 106 ovarian
cancer samples which were obtained from Memorial Sloan
Kettering Cancer Center (MSKCC) under a protocol approved
PLOS ONE | www.plosone.org

by the MSKCC Human Biospecimen Utilization Committee, a
Norwegian cohort from the Oslo University Hospital approved by
the Regional Committees for Medical and Health Research Ethics
(REC) board, the University of Michigan with a protocol approved
by the Institutional Review Boards of the University of Michigan
Medical School (IRBMED); 29 melanoma samples which were
obtained from MSKCC under a protocol approved by the
Memorial Hospital Institutional Review Board; 27 prostate cancer
samples which were obtained under clinical research approvals
9

June 2013 | Volume 8 | Issue 6 | e66264

Categories of Focal Deletions in Cancer Genomes

Figure 8. Deletion frequency of CFS-like genes in different tumor types and cancer cell lines. (A) The frequency with which the indicated
common fragile site or CFS-like gene is deleted in different primary tumors. (B) The frequency with which the indicated common fragile site or CFSlike gene is deleted in cancer cell lines.
doi:10.1371/journal.pone.0066264.g008

from the IRB of the Karolinska Hospital; and 22 glioblastoma
samples which were obtained from the Brain Tumor and NeuroOncology Center under approval of the Institutional Review
Board of the Neurological Institute of the Cleveland Clinic. This
new data has been deposited with NCBI GEO Datasets
(GSE31586). DNA and RNA were extracted from dissected tissue
containing greater than 75% tumor cell content. The 264 cell lines
were obtained from either the American Type Culture Collection
(ATCC), the Deutsche Sammlung von Mikroorganismen und
Zellkulturen (DSMZ), or the Japanese Collection of Research
Bioresources (JCRB).

PLOS ONE | www.plosone.org

Array CGH Analysis
200 ng of genomic DNA was used to make representations for
whole-genome copy number analysis by ROMA array comparative genomic hybridization as described [35]. The probes were
mapped to the March 2006 human reference sequence (NCBI
Build 36.1). Hybridizations, washing, scanning, and data normalization were performed as described [35]. The majority of cancer
samples were co-hybridized to the arrays with a differentiallylabeled unrelated reference genome, although in some cases
matching normal DNA was used as the reference. The normalized
fluorescent ratios representing DNA copy number measurements
were segmented using the CBS segmenter [37].
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Table 1. Predicted and validated fragile site genes and tumor suppressor genes ranked by focal deletion frequency.

Tumor Suppressor Gene Probability
Gene Symbol

Random Forest

Support Vector
Machine

Focal Deletion Deletion
Frequencyc
Depthd

Chromosomal
Location

Functione

Tumor suppressor genes:
CDKN2AIP/CARFa

0.78

0.96

8%

0.73

4q35.1

p14ARF/p53

CDKN2A/B

0.96

0.96

8%

0.28

9p21.3

Cdk4/Rb1/p14ARF/p53

MAD1L1a

0.97

0.95

7%

0.79

7p22.3-p22.2

Mitotic checkpoint

CSMD1a

0.99

0.81

5%

0.41

8p23.2

CUB and Sushi multiple domains

PARK7a

0.86

0.98

4%

0.71

1p36.23

Redox-sensitive chaperone

ARHGAP8a

0.93

0.87

4%

0.64

22q13.31

Rho-GTPase activating protein

UNC84Aa

0.93

0.80

3%

0.65

7p22.3

Nuclear envelope protein

RRADa

0.99

0.97

3%

0.68

16q22.1

Ras-related; associated with diabetes

MEN1

0.99

0.98

3%

0.73

11q13.1

Transcription factor

MAP2K4

0.99

0.91

3%

0.22

17p12

JNK and p38 MAP kinase signaling

FHIT

0.00

0.01

7%

0.54

3p14.2

Dinucleoside hydrolase

MACROD2b

0.01

0.02

7%

0.59

20p12.1

Macro domains

A2BP1b

0.05

0.06

5%

0.54

16p13.2

Alternative splicing factor

WWOX

0.02

0.02

5%

0.60

16q23.1

Oxidoreductase

LRP1B

0.03

0.04

4%

0.48

2q22.2-q22.1

LDL receptor-related

0.07

0.07

4%

0.53

6q26

E3 ligase

Fragile site genes:

PARK2
b

0.00

0.02

3%

0.51

5q11.2-q12.1

Phosphodiesterase

FAM190A

0.00

0.01

2%

0.54

4q22.1

Unknown

CNTNAP2

0.02

0.03

2%

0.51

17q35-q36.1

Contactin-associated protein

DLG2

0.03

0.08

2%

0.61

11q14.1

Membrane-associated guanylate cyclase

PDE4D

a

b

predicted tumor suppressor gene predicted common fragile site gene.
for deletions less than 10 Mb; does not include larger deletions.
d
deletions in CDKN2A/B, CSMD1, and MAP2K4 tend to be homozygous more often than deletions in other genes.
e
functions were assigned from the literature.
doi:10.1371/journal.pone.0066264.t001
c

window are separate (non-overlapping), then taking the average
of these values, and then standardizing this score so that is
independent of the number of deletions.
Other metrics were calculated on the level of individual
genes. ‘‘Deletion Isolation’’ was developed to quantify whether
deletions also affected nearby genes. For each gene, a gene-size
neutral metric was determined by summing the fraction of the
gene deleted in all samples. Deletion Isolation was then
determined by subtracting the average of the same metric for
both the nearest upstream and nearest downstream neighboring
genes. ‘‘Cell Line Proportion’’ was determined from the fraction
of deletions in a given gene that occurred in cell lines relative to
the total number of deletions in all sample types. ‘‘RNA/DNA
Correlation’’ for each gene was calculated from the Pearson
correlation coefficient of the log2-transformed segmented DNA
copy number value with the log2-transformed relative RNA
expression level. For genes with more than one probe on the
Nimblegen expression array (see Supplementary Methods), the
average value was used.

Identification and Validation of Focal Deletions
Common germline copy number polymorphisms (.5% frequency) were removed from the CBS segmented data by
previously described methods [35] using a masking dataset of
germline DNA copy number profiles from 500 different normal
individuals analyzed with the same platform and CBS segmentation algorithm. Thresholds for focal deletions included a minimum
of three probes per segment, a segmented DNA copy number
value that was 0.85 or below and at least 0.1 lower than both
nearest neighboring segments, and a segment size of less than
10 Mb. We validated this approach to aCGH-based determination of focal deletions by confirming the presence and boundaries
of deletions by real-time PCR using nine different TaqMan probes
(Table S7).

Deletion Metrics and Classification of Focal Deletions
The set of 10,835 focal deletions was used to develop metrics
that were based on 2 Mb intervals (windows). For genes that
were affected by 8 or more deletions, we constructed a set of
windows that contained deletions based on the deletion start
and stop positions, and assigned to the gene the values of the
closest possible window (center of gene to center of the
window). ‘‘Deletion Size’’ is the median length of all deletions
that overlap the window. ‘‘Deletion Separation’’ is calculated by
determining for each deletion how many other deletions in the
PLOS ONE | www.plosone.org

PCA and Machine Learning Tools
Principal Component Analyasis was performed for the 4,859
genes using the mean-centered and variance-adjusted seven
parameters with a built-in function from the ‘labDSV’ R software
package. We used two classifiers, Random Forest (RF) and
11

June 2013 | Volume 8 | Issue 6 | e66264

Categories of Focal Deletions in Cancer Genomes

normalization the fluorescent ratios representing DNA copy
number measurements segmented using the CBS segmenter.
Taqman probes were designed with ABI software and used as
described for both real-time PCR analyais of DNA and RNA
[10]. We constructed two A2BP1 expression vectors (pMSCVA2BP1 and pMSCV-FlagA2BP1) by using high-fidelity PCR to
amplify the coding-sequence insert from cDNA clone
AF107203.1 (alternate splicing isoform 3) with primers encoding
a wild-type N-terminus (for pMSCV-A2BP1) or using the insert
from cDNA clone NM_018723.2 (alternate splicing isoform 4)
using primers encoding a Flag-tagged N-terminus. We chose
these two isoforms for functional studies as they were the most
abundant based on annotation at http://genome.ucsc.edu. After
validation by DNA sequencing, these plasmids were transfected
into cancer cell lines and assayed for effects on tumorigenicity in
nude mice as described [10]. The tumorigenicity studies were
approved by CSHL’s Institutional Animal Care and Use
Committee (IACUC).

Support Vector Machine (SVM), to perform genome-wide
classification of deleted genes with respect to their tumor
suppressor-like or CFS-like properties. We used the Random
Forest algorithm as implemented in the randomForest R software
package (http://www.R-project.org). The algorithm was trained
on a set of 24 known tumor suppressors and 11 known common
fragile site genes (Table S4). We grew 10,000 trees each time we
generated a classifier. Initially all seven predictor variables were
used for training, resulting in correct out-of-bag classification of all
tumor suppressors and all but two common fragile site genes. The
importance of individual predictors was measured by mean
decrease of the Gini index. We then trained the classifier again,
retaining the three most important predictors: ‘‘Deletion Separation’’, ‘‘Deletion Size’’ and ‘‘Deletion Isolation’’. The quality of
out-of-bag classification was identical to that with the full set of
predictors. Finally, we applied both classifiers to the entire set of
4,823 genes focally deleted in more than 14 tumors each. The
predicted class (tumor suppressor or CFS-like) differed for only 39
genes between the two RF classifiers (Table S8). For SVM
classification, we used the Kernel-based Machine Learning Lab R
software package (http://cran.r-project.org/). We used the
Gaussian kernel, and set the kernel function parameter to 0.01
and the soft margin parameter C to 10, based on a grid search for
the best (three-fold) cross-validation error. The final crossvalidation error was 3.2% and the training error was 2.9%. To
assign class probabilities, we used the ‘prob.model’ option (Table
S8).

Supporting Information
Figure S1 Average DNA segment sizes. Plotted as a
function of position on chromosomes 2 through 13.
(EPS)
Table S1 Tumor samples, cancer cell lines, and xeno-

Co-deletion Values

grafts used in this study. This table contains four columns
describing for each sample the tumor type, sample ID, array CGH
ID, and sample type.
(XLS)

The co-deletion values were calculated by first constructing a
deletion vector for each of the 35 genes. Supposing there were only
5 samples, and gene A is deleted in sample 1 and sample 3, and
gene B is deleted in sample 2 and sample 3, then the co-deletion
value is the correlation between (1, 0, 1, 0, 0) and (0, 1, 1, 0, 0).
Only samples that contained at least 1 deletion in the set of 35
genes were used in this analysis.

Table S2 Properties of the 10,835 focal deletions. This
table contains ten columns describing for each focal deletion the
tumor type, chromosome (23 = X), chromosomal start position
(hg18), chromosomal stop position, the start and stop position on
an absolute genome scale, the segmented DNA copy number
value, the array CGH ID, and the sample type.
(XLS)
Table S3 Number of focal deletion involving individual
telomeres. Focal deletions (out of the total of 10,835) that effect
individual telomeres are shown.
(XLSX)

Expression Analysis
For a subset of the cancer samples, we performed wholegenome expression profiling using Nimblegen’s recommended
single-color hybridization protocol and their 385,000 probe gene
expression array (design ID #1877). Gene calls were generated
using the Robust Multichip Average (RMA) algorithm provided
with the NimbleScan software package. Subsequently, RMA
expression values for a given tumor type were quantile
normalized using R. Before computing the correlation between
DNA copy number and expression, the normalized RMA
expression values were log2-transformed and standardized with
values obtained with Stratagene’s universal reference RNA.

Table S4 The known common fragile site genes and
tumor suppressor genes affected by $15 focal deletions.
This set of genes was used for exploring properties that
distinguished the two classes and for the training sets for the
machine-learning tools.
(XLS)
Table S5 Differential frequency of deletions in CFS
genes between breast cancer cell lines and primary
breast tumors. This table show the numbers of breast cancer
samples affected by focal deletions in the indicated genes, broken
out by sample type (tumor or cell line). The average number of
deletions affecting RefSeq genes is shown in the last row.
(XLSX)

Biological Assays
Induction of focal deletions by replicative stress was
performed by treatment of Caco-2 cells with a subtoxic dose
(0.3 mM) of aphidicolin (Calbiochem) for 5 days followed by 24
hours recovery. Treated cells were trypsinized and 150 cells
were plated onto 10 cm plates. After two weeks, clones were
selected and expanded. Genomic DNA was isolated from each
clone using the Gentra Puregene Core kit (Qiagen) and used to
generate probes for array CGH analysis. Microarrays were
custom designed to tile the MACROD2, A2BP1, and FHIT loci
with Agilent’s eArray tool (https://earray.chem.agilent.com/
earray) using an 8615K format. Arrays were hybridized and
scanned as recommended by the manufacturer and following
PLOS ONE | www.plosone.org

Table S6 The importance of individual predictors in the

RF classifier. The mean decrease in the Gini index was used to
calculate the relative important of the seven individual properties
in the RF classifier.
(XLSX)
Table S7 Validation of focal deletion calls by TaqMan
real-time PCR. TaqMan probes were designed to nine different
locations within the A2BP1 locus and used to determine DNA
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Table S9 DNAse I hypersensitivity for six common fragile
site or CFS-like genes in four different cell types. The average
DNAse I hypersensitivity for the indicated genes was taken from
ENCODE data from the University of Washington (http://genome.
ucsc.edu/cgi-bin/hgFileUi?db = hg19&g = wgEncodeUwDnase).
Higher numbers indicate greater sensitivity and more open
chromatin structure.
(DOCX)

copy number in four different colon cancer cell lines. Shown for
each cell line are two rows comparing the DNA copy number
estimates based on aCGH versus real-time PCR. Note that there is
good agreement except for the boundary of the hemizygous
deletion in the cell line LIM2045. Real-time PCR has a greater
dynamic range and can more accurately distinguish homozygous
from heterozygous deletions than aCGH.
(XLSX)
Table S8 Functional classification of 4,823 genes for
their TSG or CFS probabilities. This table contains fourteen
columns describing for each gene with .15 focal deletions the
chromosome, chromosomal start position, chromosomal stop
position, the seven properties that distinguish TSG from CFS
genes (mean-centered and variance-adjusted), the probability of
being a TSG based on Random Forest classification (using either 7
or 3 properties), and the probability of being a TSG based on
SVM classification. The probability of being a CFS is 1– TSG
probability.
(XLS)
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